Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TH-1 Dendritic Cell Immunotherapy · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| TH-1 Dendritic Cell Immunotherapy | BIOLOGICAL | Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation. |
TH-1 Dendritic Cell Immunotherapy is an investigational cell therapy being studied for the treatment of glioblastoma, a type of brain cancer. It is designed to be used in combination with standard postoperative chemoradiation for adult patients with this condition. The therapy is currently in Phase 1 clinical development.
TH-1 Dendritic Cell Immunotherapy is being developed by The Cooper Companies, Inc. (NYSE: COO). The company is conducting clinical research on this investigational therapy for glioblastoma. As of the latest data, the therapy is in Phase 1 development.
TH-1 Dendritic Cell Immunotherapy is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. A Phase 1 trial has been completed to evaluate its use in adult patients with glioblastoma.
TH-1 Dendritic Cell Immunotherapy has been studied in one clinical trial, NCT04552886, titled 'Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma.' This Phase 1 trial enrolled 17 patients and has been completed. The trial was uncontrolled and not randomized or double-blinded.
TH-1 Dendritic Cell Immunotherapy is a type of dendritic cell therapy. The completed clinical trial NCT04552886 describes it as a dendritic cell vaccination. It is an investigational therapy being evaluated for glioblastoma, and it is not yet approved for clinical use.